These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 8679968)

  • 41. AIDS-related Kaposi's sarcoma: a phase II study of liposomal doxorubicin. The TLC D-99 Study Group.
    Cheung TW; Remick SC; Azarnia N; Proper JA; Barrueco JR; Dezube BJ
    Clin Cancer Res; 1999 Nov; 5(11):3432-7. PubMed ID: 10589755
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Low to moderate cumulative doses of pegylated liposomal doxorubicin in the treatment of classic Kaposi sarcoma in elderly patients with comorbidities.
    Potouridou I; Korfitis C; Ioannidou D; Polydorou D; Zakopoulou N; Stratigos AJ; Katsambas AD
    Br J Dermatol; 2008 Feb; 158(2):431-2. PubMed ID: 18067475
    [No Abstract]   [Full Text] [Related]  

  • 43. Kaposi's sarcoma after renal transplantation: treatment with liposomal doxorubicin.
    Boehringer M; Schwarz A; Keller F
    Nephrol Dial Transplant; 1999 May; 14(5):1342-3. PubMed ID: 10344407
    [No Abstract]   [Full Text] [Related]  

  • 44. Liposomal-doxorubicin in human immunodeficiency virus-associated Kaposi's sarcoma.
    Poizot-Martin I; Giovannini M; Rosello R; Viallat JR; Sauniere JF; Dalmas AM; Genre D; Dhiver C; Gastaut JA
    J Clin Oncol; 1994 Mar; 12(3):645. PubMed ID: 8120565
    [No Abstract]   [Full Text] [Related]  

  • 45. Pulmonary Kaposi Sarcoma.
    Gottlieb M
    CJEM; 2016 Sep; 18(5):399-400. PubMed ID: 26791020
    [No Abstract]   [Full Text] [Related]  

  • 46. Liposomal drug targeting in the treatment of Kaposi's sarcoma.
    Wernz JC
    AIDS Patient Care STDS; 1996 Dec; 10(6):362-7. PubMed ID: 11361553
    [No Abstract]   [Full Text] [Related]  

  • 47. Treatment of HIV-1-associated Kaposi's sarcoma with pegylated liposomal doxorubicin and HAART simultaneously induces effective tumor remission and CD4+ T cell recovery.
    Lichterfeld M; Qurishi N; Hoffmann C; Hochdorfer B; Brockmeyer NH; Arasteh K; Mauss S; Rockstroh JK;
    Infection; 2005 Jun; 33(3):140-7. PubMed ID: 15940415
    [TBL] [Abstract][Full Text] [Related]  

  • 48. KS: a new drug and, maybe, a new bug.
    Gilden D
    GMHC Treat Issues; 1995 Jan; 9(1):11-12. PubMed ID: 11367378
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Extravasation of liposomal daunorubicin in patients with AIDS-associated Kaposi's sarcoma: a report of four cases.
    Cabriales S; Bresnahan J; Testa D; Espina BM; Scadden DT; Ross M; Gill PS
    Oncol Nurs Forum; 1998; 25(1):67-70. PubMed ID: 9460774
    [TBL] [Abstract][Full Text] [Related]  

  • 50. New developments in Kaposi's sarcoma.
    Smart T
    GMHC Treat Issues; 1995; 9(7/8):12-7. PubMed ID: 11362652
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Early approval for two lipid-based drugs.
    Baker R
    BETA; 1995 Dec; ():4. PubMed ID: 11363009
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and tolerance of liposomal daunorubicin in Kaposi sarcoma associated with human immunodeficiency virus infection.
    Fournier S; Dupont B; Pialoux G; Eliaszewicz M; Gonzalez-Canali G; Feuillie V
    Arch Dermatol; 1997 Jul; 133(7):918-9. PubMed ID: 9236538
    [No Abstract]   [Full Text] [Related]  

  • 53. Comparative study of the antitumor activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model.
    Cabanes A; Tzemach D; Goren D; Horowitz AT; Gabizon A
    Clin Cancer Res; 1998 Feb; 4(2):499-505. PubMed ID: 9516942
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Liposomal doxorubicin.
    Tardi PG; Boman NL; Cullis PR
    J Drug Target; 1996; 4(3):129-40. PubMed ID: 8959485
    [TBL] [Abstract][Full Text] [Related]  

  • 55. DaunoXome offers KS treatment alternative.
    AIDS Alert; 1996 Jun; 11(6):67-8. PubMed ID: 11363544
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of AIDS and its attendant malignancies.
    Volberding PA; Kaplan LD
    Prog Clin Biol Res; 1989; 288():459-70. PubMed ID: 2654959
    [No Abstract]   [Full Text] [Related]  

  • 57. A multicenter phase II study of the intravenous administration of liposomal tretinoin in patients with acquired immunodeficiency syndrome-associated Kaposi's sarcoma.
    Bernstein ZP; Chanan-Khan A; Miller KC; Northfelt DW; Lopez-Berestein G; Gill PS
    Cancer; 2002 Dec; 95(12):2555-61. PubMed ID: 12467070
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Liposomal daunorubicin is not recommended in patients with less than advanced HIV-related Kaposi's sarcoma.
    White RM
    AIDS; 1997 Sep; 11(11):1412-3. PubMed ID: 9302461
    [No Abstract]   [Full Text] [Related]  

  • 59. Pharmacoeconomics of liposomal anthracycline therapy.
    Bennett CL; Calhoun EA
    Semin Oncol; 2004 Dec; 31(6 Suppl 13):191-5. PubMed ID: 15717744
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity.
    Jung SH; Jung SH; Seong H; Cho SH; Jeong KS; Shin BC
    Int J Pharm; 2009 Dec; 382(1-2):254-61. PubMed ID: 19666094
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.